Veridiana Pires de Camargo

Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial

Patrick Schöffski, Sant P. Chawla, Robert G. Maki et al. · The Lancet · 2016 · 766 citations · Full text

Medicine, Oncology, Pharmacology +12

Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor)

Veridiana Pires de Camargo, Mary Louise Keohan, David R. D’Adamo et al. · Cancer · 2010 · 214 citations · Full text

Medicine, Oncology, Chemotherapy +7

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

Jun Guo, Richard D. Carvajal, Reinhard Dummer et al. · Annals of Oncology · 2017 · 166 citations · Full text

Medicine, Oncology, Pharmacology +16

A phase 2 study of first‐line nivolumab in patients with locally advanced or metastatic cutaneous squamous‐cell carcinoma

Rodrigo Ramella Munhoz, Guilherme Nader Marta, Veridiana Pires de Camargo et al. · Cancer · 2022 · 51 citations

Pharmacy, Oncology, Pharmacotherapy +17

Neoadjuvant stereotactic ablative radiotherapy (SABR) for soft tissue sarcomas of the extremities

Elton Trigo Teixeira Leite, Rodrigo Ramella Munhoz, Veridiana Pires de Camargo et al. · Radiotherapy and Oncology · 2021 · 43 citations

Medicine, Oncology, Surgery +11